WPRIM Management System> DCMS> Chinese Journal of Digestive Surgery> 2021> 20> S2

Volume: 20 Issue: S2

1. Clinical efficacy of immunotherapy plus target therapy in the treatment of postoperative recurrence of ruptured hepatocellular carcinoma Page:1—4
2. Clinical efficacy of first-line treatment of atelizumab plus bevacizumab for recurrent hepato-cellular carcinoma after operation Page:5—9
3. Clinical efficacy of immunotherapy plus targeted therapy in the treatment of postoperative recurrence for hepatocellular carcinoma with bile duct tumor thrombus Page:10—14
4. Clinical efficacy of first-line immunotherapy plus anti-angiogenesis targeted therapy in the treatment of advanced hepatocellular carcinoma Page:15—19
5. Clinical efficacy of atezolizumab plus bevacizumab for first-line treatment of unresectable hepatocellular carcinoma Page:20—24
6. Clinical efficacy of atezolizumab plus bevacizumab in the first-line treatment of advanced hepatocellular carcinoma Page:25—28
7. Clinical efficacy of atezolizumab plus bevacizumab for the treatment of advanced hepato-cellular carcinoma Page:29—31
8. Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy in the treatment of advanced hepatocellular carcinoma Page:32—36
9. Clinical efficacy of transarterial chemoembolization combined with immunotherapy plus target therapy for advanced unresectable intrahepatic cholangiocarcinoma Page:37—40
10. Clinical efficacy of hepatic artery infusion chemotherapy combined with immunotherapy plus target therapy for advanced hepatocellular carcinoma Page:41—44
11. Clinical efficacy of restart immunotherapy for advanced hepatocellular carcinoma Page:45—48

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.